Sungyoung Lee

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva et al. · The Lancet · 2019 · 209 citations · Full text

Medicine, Clinical Sciences, Immunology +11

Associations of <i>ABCB1, ABCC2</i>, and <i>ABCG2</i> polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer

Ji‐Youn Han, Hyeong‐Seok Lim, Yeon‐Kyeong Yoo et al. · Cancer · 2007 · 197 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +16

Rare variants in <i>PPARG</i> with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes

Amit R. Majithia, Jason Flannick, Peter Shahinian et al. · Proceedings of the National Academy of Sciences · 2014 · 177 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Dae‐Hyun Yoo, Artur Racewicz, Jan Brzezicki et al. · Arthritis Research & Therapy · 2016 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

Sanguine Byun, Sungyoung Lee, Ji‐Hoon Lee et al. · Clinical Cancer Research · 2013 · 149 citations · Full text

Medicine, Oncology, Pharmacology +14